Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis
International Journal of Rheumatic Diseases · 2026-07 · 29 (7)
DOI: 10.1111/1756-185x.70756 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 26.06.2026. Verfasst von Bon San Koo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang-si, Gyeon…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Biological Products, Practice Patterns, Physicians', Healthcare Disparities. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health and Welfare, Republic of Korea (South Korea), Ministry of Health and Welfare.
Abstract (Originalsprache)
Aim
Biologic agents play a pivotal role in controlling both articular and cutaneous manifestations of psoriatic arthritis (PsA). Although international guidelines emphasize the appropriate use of biologics, Korea lacks standardized treatment protocols tailored for PsA across specialties. We therefore aimed to examine specialty‐specific prescription patterns and treatment retention using nationwide claims data.
Methods
Health Insurance Review and Assessment (HIRA) claims data from 2011 to 2022 were analyzed, including patients with PsA who initiated treatment with their first biologic agent. Patients with concurrent autoimmune diseases were excluded. Trends in diagnosis, prescription patterns, and retention were analyzed according to medical specialty.
Results
Of the 2406 patients with PsA, 63.0% were diagnosed in dermatology departments and 32.8% in internal medicine departments. Most biologics were prescribed in the dermatology department (80.2%), while 17.8% were prescribed in the internal medicine department. Since 2016, dermatology has exhibited a marked increase in both PsA diagnoses and biologic prescriptions. Interleukin‐23 (IL‐23) inhibitors were the most frequently prescribed class (62.0%), followed by IL‐17 inhibitors (21.9%) and tumor necrosis factor inhibitors (TNFi) (16.1%). Drug retention analysis revealed that dermatology was associated with a significantly higher risk of biologic discontinuation than internal medicine (hazard ratio = 1.40, 95% confidence interval 1.11–1.78).
Conclusion
The predominance of PsA diagnosis and biologic initiation in dermatology indicates substantial specialty‐specific differences in practice. This pattern warrants careful evaluation and supports the development of standardized, evidence‐based guidelines across specialties to promote appropriate care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang-si, Gyeonggi-do, South Korea.
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
ORCID-Profile: Bon San Koo, Ye-Jee Kim, Yeo-Jin Lee, Yong-Gil Kim, Tae-Hwan Kim
Förderung
- National Research Foundation of Korea
- Ministry of Health and Welfare, Republic of Korea (South Korea)
- Ministry of Health and Welfare
Zitieren
APA
Koo, B. S., Kim, Y. J., Lee, Y. J., Kim, Y. G., & Kim, T. H. (2026). Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis. International Journal of Rheumatic Diseases, 29(7). https://doi.org/10.1111/1756-185x.70756
Vancouver
Koo BS, Kim YJ, Lee YJ, Kim YG, Kim TH. Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis. International Journal of Rheumatic Diseases. 2026;29(7). doi:10.1111/1756-185x.70756
BibTeX
@article{Koo2026,
author = {Koo, Bon San and Kim, Ye-Jee and Lee, Yeo-Jin and Kim, Yong-Gil and Kim, Tae-Hwan},
title = {Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {7},
doi = {10.1111/1756-185x.70756}
}
EUVIMED